BMO Capital Believes Edwards Lifesciences (NYSE: EW) Still Has Room to Grow

By Jason Carr

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Edwards Lifesciences (NYSE: EW) yesterday and set a price target of $137. The company’s shares closed yesterday at $117.45, close to its 52-week high of $121.45.

According to, Wuensch is a 4-star analyst with an average return of 5.5% and a 59.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Edwards Lifesciences is Strong Buy and the average price target is $128, representing an 9.0% upside.

In a report issued on November 29, Canaccord Genuity also reiterated a Buy rating on the stock with a $137 price target.

Edwards Lifesciences’ market cap is currently $24.85B and has a P/E ratio of 34.14. The company has a book value ratio of 7.8585.

Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Edwards Lifesciences Corp. engages in the design, development, manufacture, and markets products to treat stage cardiovascular disease. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World.